Prelude Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Prelude Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.7K	Hold	10,000	–	–	﹤0.01%	1150
2025 Q4	$40.9K	Buy	+10,000	New	+$49.5K	﹤0.01%	1246
2024 Q3	–	Sell	-15,794	Closed	-$118K	–	1505
2024 Q2	$118K	Buy	+15,794	New	+$138K	0.01%	1083
2024 Q1	–	Sell	-19,733	Closed	-$195K	–	1503
2023 Q4	$195K	Sell	19,733 -23,226	-54%	-$166K	0.01%	949
2023 Q3	$329K	Buy	42,959 +6,573	+18%	+$65.6K	0.02%	628
2023 Q2	$272K	Buy	+36,386	New	+$255K	0.02%	691
2022 Q3	–	Sell	-18,243	Closed	-$148K	–	1865
2022 Q2	$148K	Buy	+18,243	New	+$122K	﹤0.01%	1355

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prelude Capital Management's RXRX Position: Q1 2026 in Review

Prelude Capital Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 10,000 shares worth $30.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1150.

Prelude Capital Management first reported a position in RXRX in Q2 2022 and has held it in 7 quarters since. The position peaked at $329K in Q3 2023. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Prelude Capital Management held 10,000 shares of Recursion Pharmaceuticals worth $30.7K as of Q1 2026.
Prelude Capital Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1150 holding.
Prelude Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
Prelude Capital Management's Recursion Pharmaceuticals position peaked at $329K in Q3 2023.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.